ORTHOWORLD estimates that global orthobiologic product sales account for ~10% of the orthopaedic market's revenue, overall. In 2016, that translated to just over $4.9 billion, an increase of 3% vs. 2015. For 2017 and into 2019, we're projecting similar growth.
DePuy Synthes commenced U.S. launch of TFNA Augmentation, which the company claims is the first PMMA cement system with specific trauma device indications.
DePuy Synthes is launching MAXFRAMEâ„¢, a 3D simulation assisted external circular fixation device for the treatment of limb deformity in the arm, leg, foot or ankle.Â
Orthocell appointed Surgical Specialties as exclusive distributor in Australia and New Zealand for Ortho-ATI® and Ortho-ACI® cell therapies for tendon and cartilage regeneration.Â